All News

A politician's gaffe highlights the gender gap in science. Political action, not talk, is what's needed to close it.

Scientists are moving around as never before. And, argues Jean Guinet from the OECD, that’s not necessarily a bad thing.

It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?

A new proposal from the European Investment Fund seeks to accelerate the success of European technology transfer projects. A noble idea, says Mary Lisbeth D'Amico in her fortnightly column, but no one has yet stepped up to foot the bill.

OrthoMimetics, the first technology spin-out from the Cambridge-MIT Institute, Cambridge, UK, has begun its search for initial funding.

Venture capital’s refusal to continue support helped Cyan Technology into liquidation. Rebuilt by its management, Cyan is now wary of asking VCs for money.

The pace of forming academic spin-out companies picked up in the US in 2004 after a two-year slump, according to a survey released today.

British drug-delivery company Phoqus blamed "unfavourable market" conditions for meeting only its minimum target of £10 million in its initial public offering.

Celoxica, an Oxford University spin-out that makes chip design software, blamed “depressive market” conditions for the company raising less capital than it initially expected in its initial public offering

Intercell, an Austrian biotechnology company, has received a $1 million milestone payment from Merck for progress in the development of a bacterial vaccine candidate.

Nanonucleant, a spin-out of Imperial College London, is seeking angel financing to move ahead with a glass grain-based technology that aids in crystallising proteins for study as drug targets.

"Basic research may seem very expensive. I am a well-paid scientist. My hourly wage is equal to that of a plumber..." Albert Szent-Györgyi, Nobel-winning chemist

The University of Cambridge is considering whether to make more cash available to invest in campus spin-off companies. And whatever decision it makes will come in for criticism…